KURA Earnings

KURA reported its earnings on 2026-03-05, showcasing a revenue of against an estimate of 29.81M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.72 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following KURA's earnings announcement on 2026-03-05, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, KURA's stock price tends to shift by an average of -0.94% in the 10 days leading up to earnings and 6.22% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate KURA's annual revenue to reach 81.55M, while the EPS is projected at -0.11. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between KURA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KURA's stock price typically moves by -0.94% in the 10 days before its earnings and 6.22% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.11 and revenue of 81.55M.

The earnings call highlights promising developments, particularly the FDA priority review for ziftomenib and its significant market potential. The Q&A further underscores strong confidence in product differentiation and launch readiness, despite management's evasiveness on market share expectations. The company's financials show a decrease in cash reserves due to investments, but this aligns with strategic growth. The overall sentiment is positive, with a potential stock price rise driven by the anticipated product launch and market expansion.